The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology
Open accessAbstract
Abstract At present, the only approved inhaled antipseudomonal antibiotics for chronic pulmonary infections in patients with cystic fibrosis (CF) are nebulized solutions. However, prolonged administration and cleaning times, high administration frequency, and cumbersome delivery technologies with nebulizers add to the high treatment burden in this patient population. PulmoSphere™ technology is an emulsion-based spray-drying process that enables the production of light porous particle, dry-powder formulations, which exhibit improved flow and dispersion from passive dry powder inhalers. This review explores the fundamental characteristics of PulmoSphere technology, focusing on the development of a dry powder formulation of tobramycin for the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in CF patients. This dry powder formulation provides substantially improved intrapulmonary deposition efficiency, faster delivery, and more convenient administration over nebulized formulations. The availability of more efficient and convenient treatment options may improve treatment compliance, and thereby therapeutic outcomes in CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Adherence with tobramycin inhaled solution and health care utilization
Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-5 · Cited by 95
Cited by
The use of natural and synthetic phospholipids as pharmaceutical excipients
van Hoogevest, P., & Wendel, A. (2014) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201400219 · Cited by 418
Delivery strategies for sustained drug release in the lungs
Loira-Pastoriza, C., Todoroff, J., & Vanbever, R. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 393
Drug Delivery to the lungs: Challenges and Opportunities
Newman, S. P. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0037 · Cited by 328
Technological and practical challenges of dry powder inhalers and formulations
Hoppentocht, M., Hagedoorn, P., Frijlink, H. W., & de Boer, A. H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.04.004 · Cited by 303
Metadata
- Authors
- Geller, D. E., Weers, J., & Heuerding, S.
- Venue
- Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Publisher
- SAGE Publications
- Published
- 2011-08
- Volume
- 24
- Issue
- 4
- Pages
- 175-182
- ISSN
- 1941-2703 (ISSN-L)
- 1941-2711
- OpenAlex
- W2058889783
- Cited by
- 308
- References
- 2
- FWCI
- 19.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology. https://app.cochat.ai/papers/10.1089/jamp.2010.0855
- The paper
- Geller, D. E., Weers, J., & Heuerding, S. (2011). Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology. Journal of Aerosol Medicine and Pulmonary Drug Delivery. https://doi.org/10.1089/jamp.2010.0855
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.